Literature DB >> 8328542

Recurrence of presumed varicella-zoster virus retinopathy in patients with acquired immunodeficiency syndrome.

W H Johnston1, G N Holland, R E Engstrom, S Rimmer.   

Abstract

Five patients with acquired immunodeficiency syndrome (AIDS) and presumed varicella-zoster virus retinopathy had recurrence of retinopathy after stabilization with initial intravenous antiviral therapy. Recurrences were recognized as increased retinal opacification at the borders of preexisting lesions or as new lesions. In four of the five patients, recurrences were temporally associated with a reduction in the amount of antiviral medication being received. Changes included switch from intravenous to oral acyclovir (two patients), taper of oral acyclovir (one patient), and discontinuation of medications (one patient). In four patients disease was initially unilateral; in three of these four, disease subsequently developed in the previously unaffected fellow eye at the time of recurrence. The median time from stabilization of disease to recurrence was 51 days (range, 14 to 90 days). In contrast to the management of varicella-zoster virus retinopathy in immunocompetent patients and varicella-zoster virus lesions of the skin, varicella-zoster virus retinopathy in patients with AIDS appears to require chronic suppressive antiviral therapy to prevent recurrences. In this respect it is similar to other opportunistic retinal infections in patients with AIDS. The best drugs and optimal treatment regimens for maintenance antiviral therapy remain unknown.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328542     DOI: 10.1016/s0002-9394(14)71742-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Management of varicella zoster virus retinitis in AIDS.

Authors:  R S Moorthy; D V Weinberg; S A Teich; B B Berger; J T Minturn; S Kumar; N A Rao; S M Fowell; I A Loose; L M Jampol
Journal:  Br J Ophthalmol       Date:  1997-03       Impact factor: 4.638

2.  Necrotising herpetic retinopathy in patients with advance HIV disease.

Authors:  R F Miller; N S Brink; J Cartledge; Y Sharvell; P Frith
Journal:  Genitourin Med       Date:  1997-12

Review 3.  Review: The neurobiology of varicella zoster virus infection.

Authors:  D Gilden; R Mahalingam; M A Nagel; S Pugazhenthi; R J Cohrs
Journal:  Neuropathol Appl Neurobiol       Date:  2011-08       Impact factor: 8.090

Review 4.  Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia.

Authors:  D Gilden
Journal:  J Intern Med       Date:  2011-02-23       Impact factor: 8.989

5.  Clinical and molecular aspects of varicella zoster virus infection.

Authors:  Don Gilden; Maria A Nagel; Ravi Mahalingam; Niklaus H Mueller; Elizabeth A Brazeau; Subbiah Pugazhenthi; Randall J Cohrs
Journal:  Future Neurol       Date:  2009-01-01

Review 6.  The progressive outer retinal necrosis syndrome.

Authors:  G N Holland
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

Review 7.  Varicella-zoster.

Authors:  Don Gilden; Maria A Nagel; Randall J Cohrs
Journal:  Handb Clin Neurol       Date:  2014

Review 8.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

9.  Complications of varicella zoster virus reactivation.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.972

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.